United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
Zacks
More News
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
Zacks
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Zacks
ZTS Wins European Commission Approval for New Poultry Disease Vaccine
Zoetis wins EU approval for a single-dose poultry vaccine against Newcastle and Marek's diseases, expanding its vaccine portfolio and flock protection options.
Zacks
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Zacks
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
Zacks
Reasons Why Investors Should Consider Betting on Neurocrine Stock
NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
Zacks
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
Zacks
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Pacira gains a reimbursement boost as UnitedHealthcare separately covers Exparel in outpatient care, expanding access to non-opioid postsurgical pain treatment.
Zacks
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.